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Abstract
Atopic eczema (herein referred to as ‘eczema’) is a skin disease characterized by remitting and relapsing symptoms. The
Harmonising Outcome Measures for Eczema (HOME) initiative was developed to establish a core outcome set (COS) for
eczema to be measured for all future eczema trials. The core outcome set for atopic eczema clinical trials includes the
domain for patient-reported eczema control, but a review of the validation of available eczema control instruments was
lacking. We aimed to review the literature and systematically assess the measurement properties of validated patient-
reported outcome instruments that capture eczema control. PubMed and Ovid EMBASE were searched up to 24 January
2020 for any study that reported on PROM instrument development or validation. The COnsensus-based Standards for
the selection of health Measurement Instruments (COSMIN) criteria were used to assess the quality of eligible studies.
We screened 12 036 titles and abstracts and 58 full texts. A total of 12 papers were included, reporting on seven
PROMS. These were assessed with respect to development, reliability, construct validity and responsiveness. Two
instruments, Recap of Atopic Eczema (RECAP) and the Atopic Dermatitis Control Tool (ADCT), have been developed
and validated to a sufficient standard to support their recommendation as patient-reported outcome instruments for
measuring control of atopic eczema as part of the HOME Core Outcome Set.
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Introduction
Rationale
Atopic eczema (herein referred to as ‘eczema’) is a common
chronic, inflammatory skin disease characterized by itching and
dry skin. It typically develops in children aged two years or
under, but adult onset may also occur.
Many people experience relapsing and remitting symptoms,
with periods of ‘flare’, during which their eczema worsens.1
Given this episodic nature, it is important to capture whether
patients are able to get and maintain control of their disease.
The Harmonising Outcome Measures in Eczema (HOME)
initiative aims to create a Core Outcome Set to be used in all
eczema clinical trials. During the HOME II consensus meeting
in Amsterdam in 2011, long-term control of eczema was
included through consensus vote as one of the four domains
deemed important to measure in all trials of eczema. Additional
domains included clinician-reported signs, patient-reported
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symptoms and quality of life.2 Multiple HOME meetings subse-
quently took place, but challenges arose regarding how eczema
control should be defined.
An international qualitative study including patients, parents
and clinicians suggests eczema control is a multifaceted con-
struct involving changes in disease activity, the treatment and
management of the condition and psychological, social and
physical functioning.3 It was agreed by consensus at HOME V
that the long-term control domain represents something in addition
to repeated measures of signs, symptoms, quality of life and recom-
mended addition of a patient-reported global instrument that cap-
tures eczema control.4 This review sought to identify suitable
instruments for capturing ‘eczema control’. The HOME domain of
long-term control is conceptualized as repeated measurement of
eczema control over time, in addition to the other core outcome set
domains.
A previous systematic review was conducted to explore which
strategies were available for measuring the HOME domain of
long-term control.5 However, that review was not specific to
eczema control and did not assess the methodological qualities
of the included measurement tools. The current review was
designed to identify instruments suitable for capturing the construct
of ‘global eczema control’ as recommended at the HOME V meet-
ing and evaluated the measurement properties of the identified
instruments.
Objectives
1 To identify all validated patient-reported outcome instru-
ments that capture control of eczema.
2 To systematically assess the measurement properties of those
instruments with respect to validity, consistency, reliability,
responsiveness and measurement error, guided by the COS-
MIN guidelines.
3 To provide an evidence base for future recommendations by
HOME for instruments measuring long-term control of




The study was both conducted and reported in line with the
PRISMA guidelines and was preregistered on 26 May 2020 on
PROSPERO (CRD42020162312).
Eligibility criteria
We included any study that reported on patient-reported out-
come measurement (PROM) instrument development or valida-
tion. The instruments had to be designed to capture patient-
reported control of eczema of any severity in either adults or
children. The papers had to either explicitly state that the instru-
ment measured eczema control or both reviewers had to agree that
the instrument met the following definition of eczema control ‘a
multifaceted construct involving changes in the signs and symp-
toms of eczema, psychological, social and physical functioning,
and the treatment and management of the condition’.3 Only
instruments pertaining to atopic eczema were included.
This review was designed to informHOME consensus decisions
at the HOME VII meeting in Japan.6 It was agreed at the HOME V
meeting in France that eczema control should not be measured by
flares or well-controlled weeks4 Therefore, papers that sought to
validate these measures were excluded. Quality of Life is a separate
domain for HOME purposes and therefore papers which define
control in terms of quality of life were excluded. Similarly, ‘itch’ is
a subdomain of the symptoms domain, and so papers developing
or validating measures of itch were not included. Finally, it is not
possible to undertake The COnsensus-based Standards for the
selection of health Measurement Instruments (COSMIN) assess-
ment process (see below) where only an abstract is available.
Therefore, conference abstracts were excluded.
Information sources and searches
Searches were run in Ovid Embase and PubMed on 24 January
2020 as these are the two databases for which the COSMIN filter
is available for validation studies.7 The search strategies (see
Appendix S1) combine alternative free text terms and subject
headings for three search concepts, to be combined using the
Boolean operator AND: (1) atopic dermatitis, (2) disease control
and (3) the relevant COSMIN filter for the database concerned.
There were no language restrictions.
In addition to the search of the databases above, we under-
took a survey of the membership of the HOME membership and
contacted experts in the field to identify any relevant instru-
ments that were in development.
Data collection and data items
The review followed the process set out in the COSMIN guid-
ance for systematic reviews of PROMs.8










Data were extracted in an Excel spreadsheet developed for the
review. Data extraction was performed independently by two
paired reviewers (BS, LH, RP, JC, EG, TP and ES) with adjudica-
tion by others in the study team, who had not reviewed the
instrument, in case of disagreement (JC, KT and ES). Measure-
ment properties were determined as sufficient, insufficient,
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indeterminate, not assessed or not applicable as outlined in step
two of the COSMIN assessment.9 Measurements that had insuf-
ficient content validity were deemed not to capture the construct
of interest and were therefore not assessed further.
PROMs can be developed based on a reflective or a formative
model.10 Internal consistency and structural validity are not
appropriate assessments for multi-item scales developed using a
formative model.8,11 Therefore, these have not been assessed for
PROMs developed using this approach.
Extracted information for each paper included:
• Study characteristics including author, year, country of ori-
gin and study design.
• Characteristics of the PROM including construct being
measured, the target population, the number of items and
response categories.
• Measurement properties of the instruments including con-
tent validity, ease and usefulness of interpretation and item
fit statistics.
Risk of bias
The COSMIN checklist was used to evaluate the methodological
quality of included studies. This is undertaken first for each
study individually using the COSMIN Risk of Bias checklist.9,12
For each of the measurement properties, the COSMIN check-
list consists of 5–18 items covering methodological standards
(organized in nine boxes for the nine measurement properties).
In addition, each item can be scored on a four-point scale (i.e.
‘inadequate’, ‘doubtful’, ‘adequate’ and ‘very good’). Taking the
lowest rating for each item in one box, an overall score is
obtained for each measurement property separately.
Summary measures and strategy for data synthesis
Due to the measurement properties being assessed in this review,
data have been synthesized qualitatively in accordance with the
methodology outlined in the COSMIN guidelines.
For each included PROM, the data were combined into an
overall score of sufficient, insufficient, indeterminate, not
assessed or not applicable for the measurement property.8
Risk of bias across studies
An overall GRADE of quality for that instrument has been pro-
duced (High, Moderate, Low or Very Low).
Taking into account this rating, alongside issues of inter-
pretability and feasibility, if relevant, a recommendation was
then made on the PROM or PROMs with the best validity for
use in measuring control in eczema patients. The criteria set out
by COSMIN are8 as follows:
• A – Evidence for sufficient content validity and at least low-
quality evidence of sufficient internal validity if applicable
(PROM can be recommended).
• B – PROMs that may have the potential to be recom-
mended, but further validation studies are needed.
• C – High-quality evidence for an insufficient measurement
property (PROM should not be recommended).
Results
Study selection
We identified 14 272 papers and after removing duplicates
12 036 were screened by two reviewers (BS and LH) for eligibil-
ity. One additional instrument was identified from the 106
responses received from the survey of HOME members. We
obtained 58 full texts and identified 12 eligible papers reporting
on seven instruments3,13-23 (Fig. 1).
Table 1 sets out the key characteristics of all included scales.
All scales were developed and validated in English, with the
exception of the Patient Benefit Index (PBI) 2.0 which also had a
German version. The English version of the PBI 2.0 was the one
assessed in this review. There was one single-item patient global
severity measure and five multi-item instruments. Only RECAP,
ADCT and Atopic Dermatitis Score 7 (ADS7) specified a recall
period. RECAP and ADCT were validated over a 1-week period.
ADS7 has two questions which are completed daily for 7 days
and then a total score calculated for the 7-day period based on
the daily recall. RECAP and ADS7 were validated for use in both
adults and children whilst the others were for use in adults only.
Review authors involved in the development/validation of an eli-
gible control scale were not permitted to assess their own instru-
ments.
Risk of bias
We judged all PROMs to have been developed using a forma-
tive model, and therefore, structural validity and internal con-
sistency were not assessed. None of the studies assessed
measurement error or cross-cultural validity. Table 2 sets out
the ratings.
The quality of the validation studies of the Atopic Eczema
Score of Emotional Consequences (AESEC) scored as doubtful
and ADS7 and the Impact of Chronic Skin Disease on Daily Life
(ISDL) as inadequate, on the PROM development. These were
downgraded due to the concept elicitation aspect. The methods
used to explore the relevance and the comprehensiveness of the
included questions were not conducted in a manner consistent
with the COSMIN recommendations on qualitative interview-
ing.
The quality of the RECAP and ADCT validation studies were
rated as ‘very good’ across all assessed domains.
Methodological quality and quality of evidence across
studies
The methodological quality, rated as sufficient, insufficient or
inconsistent and the GRADE rating (high/moderate/low/very
low) for each instrument is set out in Table 3.
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The AESEC was assessed as insufficient with respect to con-
tent validity. AESEC was in part developed using free-text
responses to a question via a social media platform. It is unclear
whether this approach to PROM development would elicit all
the key aspects of eczema control, nor that the final question-
naire items had been tested with the population of interest for
Table 1 Characteristics of included studies






Howells et al. 2019
Howells et al. 2020
Recap of Atopic Eczema (RECAP) UK/English 1 week Adults and children 7 97
Bhanot et al. 2020 330
Simpson et al. 2019
Pariser et al. 2020
Atopic Dermatitis Control Tool (ADCT) United States/ English 1 week Adults 6 1010
270
Blome et al. 2016
Topp et al. 2019
Patient Benefit Index (PBI) 2.0 English, German N/A Adults 24 16
64
Vakharia et al. 2018
Silverberg et al. 2018
Single-item United States/ English N/A Adults 1 265
602








N/A Adults 28 1189
Evers et al. 2008 Impact of Chronic Skin Disease on
Daily Life (ISDL)
Netherlands/English N/A Adults 16 128

























Records identified through 
survey of HOME members 
(n = 2)




Full-text articles assessed for eligibility
(n = 58)
Studies included in this study, (n = 12) 
• PBI 2.0 (n = 2)
• RECAP (n = 3)
• ADCT (n = 2)
• Single item global (n = 2)
• AESEC (n = 1)
• ISDL (n = 1)
• ADS7 (n = 1)
Records excluded
(n = 11,979)
Full-text articles excluded, with reasons, (n = 46)
• Conference abstract n = 17
• Wrong study type n = 6
• Not eczema control PROM n = 17
Records identified through database 
searching
(n = 14,271)
Figure 1 PRISMA Flow Diagram.
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comprehensibility. As such, it was not further assessed. While
lacking content validity for eczema control, it may have adequate
content for emotional consequence of the disease – its intended
purpose.
Similarly, the ADS7 was assessed as insufficient with respect
to content validity, as it was not clear how the PROM content
had been developed or validated. As such, it was also not further
assessed.
The ISDL was inconsistent with respect to content validity.
The relevance and the comprehensiveness were very good, but it
was unclear whether the response options matched the question
or were clearly understood by the intended population. The
overall PROM development was rated as inadequate, and there-
fore, the GRADE rating of the evidence was low.
The single-item patient global severity measure asks ‘Would
you describe your AD or eczema as mild, moderate or sev-
ere?’19,20 was similarly downgraded for content validity to incon-
sistent because it was unclear whether the response options were
appropriate to the concept of control. This instrument may have
appropriate content validity for patient-reported disease sever-
ity.
The study assessing responsiveness for PBI 2.0 reported that
not all hypotheses for testing responsiveness were met; therefore,
responsiveness is scored ‘inconsistent’.
Where they were reported, reliability, responsiveness and
hypothesis testing tended to be sufficient for all instruments,
with moderate to high-quality evidence.
Recommendations
Based on the risk of bias, the overall rating and the quality of the
evidence, the RECAP and ADCT scored ‘A’, suggesting that they
could be recommended for the Core Outcome Set The single-
item measure, PBI 2.0, AESEC, ISDL and ADS7 scored ‘B’, as
there was no high-quality evidence of insufficient measurement
properties, which would be the requirement for a score of C.
Discussion
The review suggests that the RECAP and ADCT were of moderate
to high quality and had sufficient evidence of good measurement
properties. Both scales are well validated by COSMIN standards
and scored an ‘A’ for the overall evidence, suggesting that they
could be considered for inclusion in the core outcome set. The
two instruments were developed independently but are similar;
both multi-items scales with a recall period of one week, validated
in English only. The questionnaires cover similar domains with
similar response values scored 0-4, though RECAP has an addi-
tional question separating itch from intense itch. Whilst RECAP
is validated for use in adults and children, ADCT is currently vali-
dated only for use in adults. Recommended cut-offs for defining
eczema control are available for ADCT but not for RECAP.
In April 2019, a preliminary version of these results, based on
scoping searches, was presented at HOME VII and used to
inform initial decisions about a recommended PROM for the
long-term control domain.6 Some results were amended follow-
ing further independent COSMIN assessments and changes to
reporting of some studies following peer review (See
Appendix S1 for summary of changes). HOME provisionally
included RECAP and ADCT in their core outcome set, subject
to further research and assessment. This review supports that
recommendation. Whilst the single-item patient global assess-
ment also was considered, HOME decided that the response
options did not adequately capture the concept of eczema con-
trol and so this could not be recommended as a global measure
of eczema control.
The AESEC and ADS7 did not have sufficient content validity
for further assessment. Based on the currently available pub-
lished literature, they are not suitable measures for eczema con-
trol, though they may capture other important aspects of the
patient’s experience of eczema. Similarly, whilst the IDSL had
some aspects that were sufficient, overall evidence was low for
content validity, which made it unlikely to be suitable as a core
measure of eczema control.
Strengths and limitations
This was a formal systematic review which followed the COS-
MIN methodology. This is a robust process that aims to provide
the best evidence for decisions about the validation of measure-
ment instruments.
However, we have only been able to assess those aspects of
validation that have been reported in the published papers. It
was not always reported whether a formative or reflective
approach to development was used. We have had to use our
Table 2 COSMIN Risk of bias checklist (Very good, adequate, doubtful and inadequate)
Instrument PROM development Reliability Hypothesis testing/
construct validity
Responsiveness
RECAP Very good Very good Very good Very good
ADCT Very good Very good Very good Very good
PBI 2.0 Adequate Not assessed Very good Very good
Single-item Adequate Not assessed Very good Very good
AESEC Doubtful Not assessed Very good Not assessed
ISDL Inadequate Not assessed Very good Very good
ADS7 Inadequate Not assessed Very good Not assessed
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judgement to determine this. It is possible that PROMs we felt
had taken a formative approach in fact used a reflective
approach. Moreover, no papers assessed measurement error or
cross-cultural validity, which are aspects that are likely to be
important for PROMs that are included in a core outcome set.
All PROMs would benefit from further validation work.
Clinical and research implications
Whilst further work is required to assess aspects of validity for
the recommended instruments, HOME has now recommended
a full Core Outcome Set, including two of the instruments
assessed in this review.6 The aim is for these to now be adopted
in all clinical trials in eczema which measure eczema control.
This review suggests that the recommended instruments have
been developed and validated in a robust process. Whilst a pre-
liminary version of this review was presented to help the atten-
dees at the HOME VII meeting reach a decision, this full review
supports the decision made during the meeting. However, it also
highlights a number of areas for each instrument that have not
been fully validated. As these instruments become more widely
used in clinical trials, researchers may wish to build in further
validation work, for example on measurement error, cross-
cultural validity and interpretability.
There is also further work to be done to understand how these
PROMS relate to one another – we do not yet know whether a
single-item patient global measure would perform as well as the
multi-item scales or whether these multi-item scales ultimately
are very similar and just one could be recommended or whether
both tools need to remain in the Core Outcome Set to fully cap-
ture this domain. Similarly, we do not know to what extent these
multi-item scales capture a construct that is truly distinct to
repeated measures of signs/symptoms/quality of life. As studies
adopt the Core Outcome Set, it may be useful to undertake sec-
ondary analyses of the collected data to explore the extent to
which these domains are truly distinct underlying constructs.
This may have the potential to reduce the Core Outcome Set
instruments and therefore reduce participant burden in future
trials.
Conclusion
RECAP and ADCT have been developed and validated to a suffi-
cient standard to support their recommendation as PROMS for
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Appendix S1. PROMs for eczema control -validation studies
review.
© 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2021
A systematic review of PROMS for eczema control 7
